Does Pelvic Irradiation Play a Role in the Management of Prostate Cancer?

ONCOLOGY

Volumn 12, Issue 10, 1998, Pages 1467-1472

  Stock, Richard G ^a   Ferrari, Anna C ^a   Stone, Nelson N ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; HUMAN; LYMPH NODE METASTASIS; MALE; METHODOLOGY; PELVIS; PROSTATE TUMOR; RADIATION DOSE; RADIOTHERAPY; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS; HUMANS; LYMPHATIC METASTASIS; MALE; PELVIS; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 0032185725     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Flocks RH, Culp D, Porto R: Lymphatic spread from prostate cancer. J Urol 81:19-24, 1959.
2. Gervasi LA, Mata J, Easley JD, et al: Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 142:332-336, 1989.
3. Lieskovsky G, Skinner DG, Weisenburger T: Pelvic lymphadenectomy in the management of carcinoma of the prostate. J Urol 124:635-638, 1980.
4. McLaughlin AP, Saltzstein SL, McCullough DL, et al: Prostatic carcinoma: Incidence and location of unsuspected lymphatic metastases. J Urol 115:89-94, 1976.
5. Paulson DF: The impact of current staging procedures in assessing disease extent of prostatic adenocarcinoma. J Urol 121:300-302, 1979.
6. Donohue RE, Mani JH, Whitesel JA, et al: Pelvic lymph node dissection: Guide to patient management in clinically locally confined adenocarcinoma of prostate. Urology 20:559-565, 1982.
7. Bishoff JT, Reyes A, Thompson IA, et al: Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: Development of a system of patient selection. Urology 45:270-274, 1994
8. Danella JF, deKernion JB, Smith RB, et al: The contemporary incidence of lymph node metastases in prostate cancer: Implications for laparoscopic lymph node dissection. J Urol 149:1488-1491, 1993.
9. Stock RG, Stone NN, Ianuzzi C, et al: Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: Implications for patient selection in the radiotherapeutic management of prostate cancer, Int J Radiat Oncol Biol Phys 33:815-821, 1995.
10. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 277:1445-1451, 1997.
11. Leibel SA, Fuks Z, Zelefsky MJ, et al: The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 28:7-16, 1993.
12. Kramer SA, Cline WA Jr, Farnham R, et al: Prognosis of patients with stage D1 prostatic adenocarcinoma. J Urol 125:817-819, 1981.
13. Paulson DF: The prognostic role of lymphadenectomy in adenocarcinoma of the prostate. Urol Clin North Am 7:615-622, 1980.
14. Sause WT, Richard RS, Plenk H: Prostatic carcinoma: 5-Year follow-up of patients with surgically staged disease undergoing extended field radiation. J Urol 135:517-519, 1986.
15. Steinberg GD, Epstein JI, Piantadosi S, et al: Management of stage D1 adenocarcinoma of the prostate. The Johns Hopkins experience, 1974 to 1987. J Urol 144:1425-1432, 1990.
16. Anscher MA, Prosnitz LR: Prognostic significance of extent of nodal involvement in stage D1 prostate cancer treated with radiotherapy. Urology 39:39-43, 1992.
17. Davidson PJ, Hop W, Kurth KH, et al: Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage T0 to T4, N1 to 3, M0, D1). J Urol 154 2118-2122, 1995.
18. Golimbu M, Provet J, Al-Askari S, et al: Radical prostatectomy for D1 prostate cancer. Urology 30:427-435, 1987.
19. Zincke H, Bergstralh EJ, Larson KJ, et al: Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment: Evidence for favorable survival in patients with DNA diploid rumors. Cancer 70:311-323, 1992.
20. Hellman S: Natural history of breast cancer. J Clin Oncol 12:2229-2234, 1994.
21. Leibel SA, Scott C, Mohiuddin M, et al: The effect of local regional control on distant metastatic dissemination in carcinoma of the head and neck: Results of an analysis from the RTOG head and neck database. Int J Radiat Oncol Biol Phys 21:549-556, 1990.
22. Stock RG, Chen ASJ, Karasek K: Patterns of spread in node-positive cervical cancer: The relationship between local control and distant metastases. Cancer J Sci Am 2:256-262, 1996.
23. Israeli RS, Miller-WH J, Su SL, et al: Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J Urol 153:573-577, 1995.
24. Katz AE, de VG, Benson MC, et al: The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. Urol Clin North Am 23-541-549, 1996.
25. Ferrari AC, Stone NN, Eyler JN, et al: Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer. J Natl Cancer Inst 89:1498-1504, 1997.
26. Edelstein RA, Zietman AL, De-Las Morenas A, et al: Implications of prostate micrometastases in pelvic lymph nodes: An archival tissue study. Urology 47:370-375, 1996.
27. Aristizabal SA, Steinbronn D, Heusinkveld RS: External beam radiotherapy in cancer of the prostate. The University of Arizona experience. Radiother Oncol 1:309-315, 1984.
28. Hanks GE, Buzydlowski J, Sause WT, et al: Ten year outcomes for pathologic node-positive patients treated in RTOG 75-06. Int J Radiat Oncol Biol Phys 40:765-768, 1998.
29. Lawton CA, Cox JD, Glisch C, et al: Is long-term survival possible with external beam irradiation for stage D1 adcnocarcinoma of the prostate? Cancer 69:2761-2766, 1992.
30. Bezzi M, Kressel HY, Allen KS, et al: Prostatic carcinoma: Staging with MR imaging at 1.5 T. Radiology 169:339-346, 1988.
31. Flanigan RC, McKay TC, Olson M, et al: Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology 48:428-432, 1996.
32. Hanks GE, Krall JM, Pilepich MV, et al: Comparison of pathologic and clinical evaluation of lymph nodes in prostate cancer: Implications of RTOG data for patient management and trial design and stratification, Int J Radiat Oncol Biol Phys 23:293-298, 1992.
33. Hricak H: Non-invasive imaging for staging of prostate cancer: Magnetic resonance imaging, computed tomography, and ultrasound. NCI Monograph 7:31-36, 1988.
34. Ploysongsang S, Scott RM, Aron BS, et al: Comparison of whole pelvic versus small-field radiation therapy for carcinoma of the prostate. Urology 27:10-16, 1986.
35. Whittington R, Malkowicz SB, Machtay M et al: The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer. Int J Radiat Oncol Biol Phys 39:673-680, 1997.
36. Sands ME, Pollack A, Zagars GK: Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. Int J Radiat Oncol Biol Phys 31:13-19, 1995.
37. Lawton CA, Winter K, Byhardt R, et al: Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31): Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 38:931-939, 1997.
38. Cheng CW, Bergstralh EJ, Zincke H: Stage D1 prostate cancer: A nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer 71:996-1004, 1993.
39. Morris AD, Zeitman AL, Althausen AF, et al: The value of external beam radiation in pathologic node positive prostate cancer: A multivariate analysis. Int J Radiat Oncol Biol Phys 39:217, 1997.
40. Asbell SO, Martz KL, Shin KH, et al: Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06: A phase III study for T1BNOMO (A2) and T2NOMO (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 40:769-782, 1998.
41. McGowan DG: The value of extended field radiation therapy in carcinoma of the prostate. Int J Radiat Oncol Biol Phys 7:1333-1339, 1981.
42. Rasp GM, Pisansky TM, Haddock MG, et al: Elective pelvic nodal irradiation in patients with clinically localized prostate cancer at high risk for pelvic nodal involvement. Int J Radiat Oncol Biol Phys 36:245-245, 1996.
43. Seaward SA, Weinberg V, Lewis P, et al: Improved freedom from PSA failure with whole pelvic irradiation for high risk prostate cancer. Int J Radiat Oncol Biol Phys 39:222-222, 1997.
44. Bolla M, Gonzalez D, Padraig W, et al: Improved survival in patients with clinically advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997.
45. Laverdiere J, Gomez JL, Leonelo C, et al: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37:247-252, 1997.
46. Pilepich MV, Sause WT, Shipley WU, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616-623, 1995.
47. Perez CA, Michalski J, Brown KG, et al: Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 36:573-584, 1996.